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INTRODUCTION
High-dose chemotherapy followed by the infusion of
autologous peripheral blood stem cells (PBSC) can signiﬁ-
cantly improve the initial response rates and overall survival
rates for some cancer patients [1-3]. However, the major
cause of treatment failure remains relapse. To reduce the
incidence of relapse due to contaminant tumor cells in the
stem cell product [4-6], CD34 selection of PBSC has been
used. The infusion of CD34-selected PBSC is associated
with a slower reconstitution of the immune system, which
may lead to a higher rate of infectious complications [7-9].
Mechanistically, this increased risk is likely due to the
removal of T-cells, natural killer (NK) cells, and monocytes
that occurs during the selection procedure.
A higher incidence of infections after myeloablative ther-
apy among recipients of allogeneic CD34-selected PBSC
transplantation compared to recipients of autologous CD34-
selected PBSC transplantation has already been described
[10-12]. A recent study from our institution showed a signiﬁ-
cantly increased incidence of cytomegalovirus (CMV) disease
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ABSTRACT
CD34 selection of peripheral hematopoietic blood stem cell products has been applied to reduce the risk of relapse
after an autologous transplantation. However, CD34 selection is also associated with a significant reduction in T-cells,
natural killer cells, and monocytes, and these reductions may influence immune reconstitution and thus increase
the risk for infections. An increased incidence of cytomegalovirus (CMV) disease in patients receiving CD34-
selected transplants has been reported. In this study, the incidence rate of infections other than CMV is reported
in 32 patients who underwent myeloablative therapy followed by the infusion of CD34-selected autologous periph-
eral blood stem cells (PBSC) and compared to the rate in a contemporaneous group of 273 patients who received
unselected autologous PBSC during the same time period. Infection surveillance and prevention strategies were
identical between the 2 groups. More non-CMV infections occurred in the recipients of CD34-selected PBSC
than in recipients of unselected PBSC (78% versus 30%, P < .0001). The differences in the rates of viral infec-
tions were mainly due to dermatomal and disseminated varicella-zoster virus (VZV) (any VZV, 26% versus 4%,
P = .002; disseminated VZV, 11% versus 0.3%, P = .03) and parainfluenza 3 virus infections (13% versus 3%, P = .04).
Bacterial infections were also more common among CD34-selected PBSC transplant recipients (34% versus 16%,
P = .01), whereas fungal infections were not significantly different between the groups. In multivariable logistic
regression models, the effect of CD34 selection on infection risk remained significant for viral infections and
overall non-CMV infections. Infection-related mortality was not significantly different between the groups. In
conclusion, the incidence of viral and bacterial infections appears to be increased in recipients of CD34-selected
autologous PBSC transplants. Because the risk for infections approaches that seen in allogeneic transplant recipi-
ents, infection surveillance, diagnostic work-up, and prevention strategies similar to those used in allogeneic
recipients are warranted.
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in CMV-seropositive recipients of autologous CD34-selected
PBSC compared to recipients of unselected autologous
CD34 PBSC [10].
In this report we describe our experience with oppor-
tunistic infections other than CMV in autologous CD34-
selected PBSC transplant recipients.
MATERIALS AND METHODS
Patients and Study Design
Between April 1995 and November 1998, patients
received myeloablative therapy followed by the infusion of
either autologous CD34-selected PBSC (n = 32) or autolo-
gous CD34-unselected PBSC (n = 273). Patients were
treated in a nonrandomized fashion according to the speciﬁc
protocol active at the time of enrollment or at the discretion
of the attending physician. Patients were treated either at
the Fred Hutchinson Cancer Research Center (FHCRC) or
at the Veterans Affairs Medical Center, both in Seattle,
Washington. Both institutions used similar infectious sur-
veillance strategies and prophylaxis therapy. After informed
consent had been obtained, all patients were treated accord-
ing to protocols approved by the institutional review board
(IRB) of the hospital where therapy was administered.
Patients were evaluated for the first 100 days after trans-
plantation for the development of infections. This analysis
was approved by the IRB at FHCRC.
Mobilization, Collection, and Cryopreservation 
of PBSC
PBSC were mobilized using either recombinant granu-
locyte colony-stimulating factor (G-CSF; Amgen, Thou-
sand Oaks, CA) alone or intermediate-dose chemotherapy
followed by either G-CSF or granulocyte-macrophage
(GM)-CSF (Immunex, Seattle, WA). For 26 patients, a sec-
ond mobilization was necessary either because an insuffi-
cient number of cells were collected at the ﬁrst mobilization
or because there was tumor contamination of the product.
All PBSC collections were preformed using the COBE
Spectra device (COBE BCT, Lakewood, CO), and all prod-
ucts were cryopreserved with dimethyl sulfoxide as previ-
ously described [10]. CD34 selection was performed using
the Baxter 300 Isolex System (Baxter, Irvine, CA) (n = 18)
and the Cellpro Ceprate System (Cellpro, Seattle, WA)
(n = 14) according to the manufacturer’s specifications as
previously described [10].
Transplantation Conditioning
Patients in both groups received a variety of high-dose
myeloablative regimens, with or without total body irradia-
tion (TBI), in preparation for transplantation (Table 1).
Infection Surveillance and Supportive Care
All patients were monitored for the ﬁrst 100 days after
transplantation for the development of non-CMV viral,
fungal, and bacterial infections. Bacterial and fungal blood
cultures were performed when patients had fever (>38°C).
Patients who were receiving systemic corticosteroids had
bacterial and fungal blood cultures performed routinely
once a week regardless of fever. Patients with any upper res-
piratory symptoms had a nasal wash performed, and patients
with pneumonia were evaluated by bronchoalveolar lavage
(BAL) and/or lung biopsy. Viral direct ﬂuorescent antibody
(DFA) staining and culture were performed on all nasal
wash, BAL, lung biopsy, and autopsy specimens throughout
the study period. Cultures for respiratory viruses were inoc-
ulated into tissue cultures containing 3 cell types: rhesus
monkey kidney, human foreskin ﬁbroblasts, and A-549 cells.
Upper respiratory cultures were kept for 10 days before
reporting results as negative; lower respiratory tract cultures
were kept for at least 21 days. All BAL, biopsy, and autopsy
specimens were also submitted for routine bacterial, fungal,
and acid-fast bacilli cultures, and DFA staining and culture
were performed for Legionella species. Cytospins were per-
formed for herpes simplex virus (HSV), and shell vial cen-
trifugation cultures for respiratory syncytial virus (RSV)
were also performed.
Following myeloablative therapy, all patients received
prophylactic antibiotics when the absolute neutrophil count
(ANC) reached < 0.5 × 109/L. Patients who were serologi-
cally positive for HSV received prophylactic low-dose acy-
clovir. Antifungal prophylaxis with ﬂuconazole (400 mg/day)
was given to all patients from the start of conditioning to
day 75 after transplantation [13]. Prophylaxis against Pneu-
mocystis carinii consisted of trimethoprim-sulfamethoxazole
as ﬁrst-line treatment and dapsone as second-line treatment
until day 120 after transplantation. Because of limitations in
drug availability, prophylactic intravenous immunoglobulin
was administered to only 6 of the 10 chronic lymphocytic
leukemia and multiple myeloma patients who received
CD34-selected PBSC. At the discretion of the attending
physician or per protocol, 9 (28%) of the 32 patients who
underwent CD34-selected PBSC transplantation received
posttransplantation growth factor until engraftment, either
G-CSF 5 µg/kg per day subcutaneously (sc) (n = 7), G-CSF
10 µg/kg per day sc (n = 1), or GM-CSF 500 µg/m2 per day
sc until 14 days posttransplantation followed by G-CSF
5 µg/kg/day sc (n = 1). Twelve (4.4%) of the 273 patients
who underwent unselected PBSC transplantations received
G-CSF 5 µg/kg per day sc until engraftment.
Definitions
The day of onset of an infection was deﬁned as the day
when the diagnostic test was performed. Brieﬂy, infections due
to respiratory viruses were categorized as upper respiratory
tract infections if the virus was detected in nose-pharyngeal/
throat washes or swabs, sinuses, or sputum with no symp-
toms or clinical evidence of lower respiratory tract infection.
Lower respiratory tract infections were deﬁned as detection
of respiratory viruses in BAL or biopsy by culture methods
or DFA tests in association with new or changing pulmonary
infiltrates on chest radiograph and lower respiratory tract
symptoms. HSV infections were deﬁned as speciﬁc detection
of HSV in culture or by DFA staining in association with
typical clinical lesions [14]. Varicella-zoster virus (VZV)
infections were deﬁned as typical cutaneous vesicular lesions
and the detection of VZV by culture or DFA [15].
The National Institutes of Health Mycosis Study
Group/European Organization for Research and Treatment
of Cancer consensus definitions for invasive fungal infec-
tions were used [16]. Proven invasive mold infections were
deﬁned as histopathologic or cytopathologic demonstration
Infections after CD34-Selected PBSC Transplantation
283B B & M T
of fungal tissue invasion or a positive culture obtained from
a sterile site in concordance with a clinical picture of infec-
tion. Probable invasive fungal infections were defined as
positive culture or cytological evidence of mold from BAL
in association with typical radiological signs on computer-
ized tomography. Fungemia was any positive blood culture
for yeast or Fusarium.
Bacterial infections were categorized as bacteremias and
site-speciﬁc infections. Multiple positive blood cultures for
different organisms on the same day were considered a single
polymicrobial bacteremia. Recurrent bacteremia was deﬁned
as a positive blood culture of an organism occurring anytime
after the initial positive culture for a different organism. Any
positive cultures for a given organism within the ﬁrst 21 days
of a positive blood culture for that organism were considered
to belong to the same infectious event. Site-speciﬁc bacterial
infections were deﬁned as evidence of bacterial infection by
culture of a normally sterile site or by culture and evidence
of tissue invasion of a nonsterile site by histology. For
patients with multiple infections of a particular type, only
their ﬁrst infection contributed to incidence comparisons.
Neutrophil engraftment was defined as the first of
3 consecutive days on which the ANC exceeded 0.5 × 109/L
after transplantation. Neutropenic enterocolitis was deﬁned
as a syndrome of abdominal pain, profound neutropenia
(<100/mm3), and typical ﬁndings on computerized tomogra-
phy [17]. The use of corticosteroids was deﬁned as a dosage
of ≥0.5 mg/kg per day for at least 3 consecutive days.
Statistical Analysis
Summary statistics included frequency counts and per-
centages for categorical variables. Median and range for con-
tinuous variables were also calculated. Comparisons from 2 × 2
tables were made using chi-square and Fisher exact tests, as
appropriate. Cumulative incidence curves up to 100 days
posttransplantation were produced for non-CMV viral, fun-
gal, bacterial, and overall infection. For each infection cate-
gory, univariate and multivariable logistic regression models
were used to analyze the influence of CD34 selection and
other variables on the risk of infection. Multivariable models
with CD34 selection as the primary parameter of interest
were ﬁt by including each of the other variables in a stepwise
fashion. Only those variables whose inclusion altered the
coefficient estimate of CD34 selection by more than 10%
were kept in the models. The survival rate after infection
among recipients of CD34-selected PBSC transplantations
Table 1. Characteristics of Patients Who Underwent PBSC Autologous Transplantation
Characteristics CD34-Selected Unselected
No. of patients 32 273
Age, median (range), y 51 (6-67) 47 (2-69)
Sex, M/F 19/13 108/165
CMV-positive serology pretransplantation, n 18 (55%) 170 (63%)
VZV-positive serology pretransplantation, n 19 (59%) 160 (59%)
HSV positive serology pretransplantation, n 21 (66%) 148 (54%)
Diagnosis, n
Multiple myeloma 8 (24%) 38 (14%)
Non-Hodgkin’s lymphoma 8 (24%) 51 (19%)
Hodgkin’s disease 0 16 (6%)
Acute lymphocytic leukemia 1 (3%) 1 (0.4%)
Myelodysplastic syndrome 0 2 (0.7%)
Acute myelogenous leukemia 0 10 (4%)
Chronic myelogenous leukemia 0 5 (2%)
Chronic lymphocytic leukemia 6 (18%) 0
Neuroblastoma 1 (3%) 15 (6%)
Breast cancer 1 (3%) 97 (36%)
Ovarian cancer 0 16 (6%)
Germ cell tumor 0 3 (1%)
Brain cancer 0 1 (0.4%)
Sarcoma 0 12 (4%)
Carcinoma 0 6 (2%)
Systemic sclerosis 5 (15%) 0
Multiple sclerosis 2 (6%) 0
Prior chemotherapy
No. of cycles, median (range) 6 (0-27) 6 (0-25)
High-dose conditioning regimen, n
With TBI 19 (59%) 36 (13%)
Without TBI 13 (41%) 237 (87%)
No. of CD34-infused cells, ×106 cells/kg, median (range) 4.6 (2.3-11.3) 6.4 (1.5-65.8)
No. of days to neutrophil engraftment, median (range) 12 (8-21) 11 (7-135)
Absolute lymphocyte count/mm3 at day 30, median (range)* 738 (150-2954) 1160 (80-8380)
Absolute monocyte count/mm3 at day 30, median (range)* 455 (0-1710) 700 (30-3337)
Posttransplantation corticosteroids 15 (47%) 90 (33%)
*Measurements obtained at ±5 days in a subgroup of patients with available data (CD34-selected, n = 26; unmodiﬁed, n = 217).
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with diagnosis of an infection was compared to that of recipi-
ents of unselected PBSC transplantations with infections
using Kaplan-Meier curves and log-rank tests.
RESULTS
Patient Characteristics
A total of 305 patients received an autologous PBSC
transplant during the study period; 273 patients received
unselected CD34 and 32 patients received selected CD34
PBSC (characteristics are shown in Table 1). The underly-
ing disease categories and conditioning regimens differed
between the 2 transplant types because of the protocol
inclusion criteria. Accordingly, there was an imbalance in
the overall proportion of patients with hematological malig-
nancies (23 [72%] of 32 patients receiving CD34-selected
PBSC versus 123 [45%] of 273 patients receiving unselected
PBSC, P = .004) and in the use of TBI-containing regimens
(19 [59%] of 32 patients versus 36 [13%] of 273 patients,
respectively, P < .001). The proportion of patients requiring
a second collection because of poor yield or tumor contami-
nation was higher in the group that received CD34-selected
PBSC (7 [22%] of 32 patients versus 19 [7%] of 273 patients,
P = .01); however, this difference was mainly due to a higher
rate of tumor contamination. There was no difference in the
proportion of re-collections due to insufﬁcient numbers of
cells (2 [6%] of 32 patients versus 12 [4%] of 273 patients,
P = .6). Absolute lymphocyte and monocyte counts at
approximately day 30 after transplantation were different
between the groups (P = .002). Similar percentages of
patients in the 2 groups received steroid therapy (P = .1)
with methylprednisolone 1 to 2 mg/kg per diem for the
treatment of regimen-related toxicities.
Incidence of Infections and Timing of Diagnosis
We initially evaluated the cumulative incidence of inva-
sive viral (non-CMV), fungal, bacterial, and all infections
in recipients of CD34-selected and -unselected PBSC (Fig-
ure 1). We then performed an analysis by speciﬁc organisms
(Table 2, Figure 2). The median days from transplantation
to diagnosis for viral infections were 30 days in recipients of
CD34-selected PBSC and 32 days in recipients of unse-
lected PBSC; for invasive fungal infections, the medians
were 17 and 24 days, respectively; and for bacterial infec-
tions, the medians were 16 and 16 days, respectively. The
difference seen in viral infections appeared to be mainly due
to more VZV and parainﬂuenza 3 infections (P = .002 and
P = .04, respectively) (Table 2, Figure 2). The median days
to onset of VZV infections were 47 days (range, 6-81 days)
in recipients of CD34-selected transplants and 62 days (range,
26-105 days) in recipients of unmodified transplants; the
corresponding ﬁgures for parainﬂuenzavirus 3 infections were
32 days (range, 4-70 days) and 49 days (range, 1-102 days),
respectively. Most patients who developed VZV infections
Figure 1. Cumulative incidence of any invasive fungal infections, any viral infections (other than CMV), a bacteremia/bacterial site infection (other
than coagulase-negative staphylococcal bacteremia), and any non-CMV invasive infections.
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were VZV seropositive before transplantation (Table 2).
The proportion of disseminated disease was 2 (40%) of
5 recipients of CD34-selected transplants compared to
1 (17%) of 6 recipients of unmodiﬁed transplants. Overall,
the proportion of disseminated disease was higher in CD34-
selected transplant recipients (2 [6%] of 32 patients versus
1 [0.4%] of 273 patients, P = .03). The 2 patients who devel-
oped VZV infection early after CD34-selected infusion (day
6 and day 12) received prophylaxis with acyclovir because of
pretransplantation positivity for HSV. None of the other
patients who developed a VZV infection were receiving
antiviral therapy at the time of onset of infection. There was
no significant difference in VZV infection between pre-
transplantation seronegative patients and those with
unknown VZV serostatus (1 of 13 recipients of CD34-
selected and 2 of 113 recipients of unmodiﬁed PBSC).
There was a trend toward more invasive fungal infec-
tions among recipients of CD34-selected PBSC (P = .07).
All cases of candidemia occurred during fluconazole pro-
phylaxis. All species were nonalbicans (Candida parapsilosis, n
= 5; Candida glabrata, n = 2; 1 patient with hepatosplenic
candidiasis, organism not speciﬁed).
For invasive bacterial infections, there was no difference
between the 2 groups in the incidence of non–central ner-
vous system bacteremia (P = .12), and there was also no pre-
dominant organism in either group (data not shown); the
proportion of gram-negative bacteremia was not different.
However, there seemed to be more bacterial site infections
in the group that received CD34-selected PBSC (P = .04)
(Table 2). When only patients with hematological malignan-
cies were considered, there was no qualitative difference in
the infection rates (Figures 2B and 2D and Table 3).
Risk Factors for Infections
Risk factors for the different infection categories were
analyzed in univariate and multivariate logistic regression
models (Table 3). In univariate analysis, CD34 selection was
a risk factor for any non-CMV infection. Speciﬁcally, viral
and bacterial infections were increased in recipients of
CD34-selected PBSC, whereas the rates of fungal infections
were not statistically different between the groups. When
potentially confounding variables were analyzed (ie, age, sex,
use of TBI, use of corticosteroids, CMV serostatus prior to
transplantation, underlying disease [hematological versus
nonhematological malignancies], absolute lymphocyte and
monocyte counts of <300/mm3 at day 30), only the follow-
ing factors were found to be signiﬁcant: for viral infections,
the use of corticosteroids and CMV serostatus prior to
transplantation; for fungal infections, the use of TBI and a
low monocyte count at day 30; and for invasive bacterial
infections, CMV-negative serostatus prior to transplantation
(Table 3). CMV reactivation (any pp65 antigenemia or
blood culture) was not significantly associated with any of
the infection categories or overall infections. In multivariate
logistic regression models that included these factors, the
effect of CD34 selection on infection risk remained signiﬁ-
cant for viral infections and all infections. For bacterial
infections, that effect became only marginally significant
when TBI was added to the model. For fungal infections,
CD34 selection was not associated with a higher risk even
after controlling for other factors. However, late monocyte
engraftment, use of TBI, and recipient sex appeared to be
important factors. CMV serostatus did not appreciably
change the effect of CD34 in the multivariate models of any
of the infection categories.
Table 2. Incidence of Speciﬁc Infections before Day 100*
Type of Infection CD34-Selected (n = 32) Unselected (n = 273) P
Non-CMV viral infections 17 (53%) 39 (14%) <.0001
RSV 2 (6%) 5 (2%) .2
Upper respiratory tract infections 1 (3%) 2 (0.7%) .3
Lower respiratory tract infections 1 (3%) 3 (1%) .4
Parainfluenzavirus 3 4 (13%) 9 (3%) .04
Upper respiratory tract infections 2 (6%) 5 (2%) .2
Lower respiratory tract infections 2 (6%) 4 (1%) .1
VZV† 5 (26%) 6 (4%) .002
Dermatomal 3 (16%) 5 (3%) .04
Disseminated/visceral 2 (11%) 1 (0.6%) .03
HSV† 4 (18%) 14 (9%) .24
Fungal infections
Overall 4 (13%) 12 (4%) .07
Candida‡ 2 (6%) 7 (3%) .24
Aspergillus 2 (6%) 5 (2%) .2
Bacterial infections
Bacteremia (other than due to coagulase-negative staphylococci) 8 (25%) 39 (14%) .12
Bacterial site infections 3 (9%) 5 (2%) .04
Bacterial infections (site + bacteremias) 11 (34%) 44 (16%) .01
Any infection other than CMV 25 (78%) 81 (30%) <.0001
*Four infections shortly after day 100 were included; all occurred in recipients of unmodiﬁed PBSC.
†Among seropositive individuals. For VZV, there were 19 seropositive recipients of CD34 products and 160 recipients of unmodiﬁed products;
1 and 2 additional cases, respectively, occurred in patients with seronegative serology or missing serostatus information (P not signiﬁcant). For
HSV, there were 22 and 161 seropositive recipients, respectively; 1 and 4 cases, respectively, occurred in patients with seronegative or missing
serology (P not signiﬁcant).
‡Includes 1 case of Rhodotorula fungemia (yeast).
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Outcome of Infections
Overall mortality for CD34-selected versus unmodiﬁed
transplant recipients in the different infection categories was
analyzed by the Kaplan-Meier method. There was no statis-
tically significant difference in the time to death for any
infection (Figure 3), viral infections (P = .8), invasive fungal
infections (P = .7), or invasive bacterial infections (P = .9).
DISCUSSION
Our analysis shows a higher incidence of non-CMV
infections in patients who underwent CD34-selected autol-
ogous transplantation when compared to that in patients
who underwent unselected PBSC transplantation. This dif-
ference in infection rates is mostly related to the higher
frequency of viral (ie, VZV and parainfluenzavirus 3) and
invasive bacterial infections. Both the incidence and the
severity of these infections were increased in CD34-selected
transplant recipients, ie, more disseminated VZV infections
and more bacterial site infections.
In an earlier study, we showed that CMV disease is
more common in CD34-selected autograft recipients [10].
Others reported similar results [18,19]. The higher inci-
dence of another herpesvirus infection, ie, VZV, supports
the hypothesis that CD34-selected autograft recipients have
a higher risk of herpesvirus reactivation. VZV infection pre-
dominantly occurred in VZV-seropositive recipients, and
there was also a higher risk of disseminated disease. The
early onset of VZV infection is particularly interesting
because VZV infection is considered a late complication
after hematopoietic stem cell transplantation (HSCT) [15].
The underlying mechanism is likely a delayed T-cell recon-
stitution following transplantation of a CD34-selected graft,
which is usually T-cell– depleted by 2 to 3 log [20]. Accord-
ingly, our cohort had delayed engraftment of lymphocytes
and monocytes (Table 1). When entered into the statistical
model, the rate of lymphocytopenia at day 30 was not statis-
tically significant, but the overall numbers were small and
virus-speciﬁc immunity was not measured. The increase of
parainfluenzavirus 3 infections, including pneumonia, was
unexpected. Parainﬂuenzavirus infections occur in approxi-
mately 7% to 10% of HSCT recipients in large series [21].
However, this infection is rarely seen in recipients of unse-
lected autologous transplant, and pneumonia seems to be
Figure 2. Incidence of infections by category and organisms before day 100 after transplantation in CD34-selected versus unmodiﬁed PBSC trans-
plant recipients in all patients (A and C) and in the subgroup of patients with hematological malignancies (B and D). 
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extremely rare in this setting. A recent risk factor analysis of
parainfluenzavirus 3 pneumonia has identified acute graft-
versus-host disease and use of corticosteroids as important
factors for the progression from upper to lower respiratory
tract disease [22]. In the present analysis, CD34 selection
remained statistically significant for viral infections after
controlling for corticosteroid use. Thus, CD34 selection
may be an additional factor that may put patients at risk for
this complication, possibly mediated through an impaired
T-cell immunity.
Our results and other studies point to a profound
immunodeﬁciency early after the infusion of CD34-selected
PBSC compared with unselected autologous PBSC. Lemoli
et al. studied 14 patients with multiple myeloma who
received CD34-selected PBSC [7] and found that posttrans-
plantation absolute CD4 count was lower than pretreatment
levels. Bomberger et al. [9] reported that the restoration of
normal numbers of both T- and B-cells was delayed during
the first 2 months after infusion of CD34-selected PBSC.
Mainly CD4–CD8+, (α/β T-cell receptor+, CD45Ro+, and
CD45RA– cells were noted to be circulating. After the infu-
sion of CD34-selected PBSC, there is a loss of the diversity
normally seen in the T-cell repertoire after infusion of
unselected PBSC. Rutella et al. [8] reported on their obser-
vation of recovery of lymphocyte counts, CD4+, CD8+ T-cell
subsets, NK, and CD19+ cells in CD34-selected and unse-
Table 3. Risk Factor Analysis*
Univariate Multivariable†
Type of Infection OR 95% CI P Adjusted OR 95% CI P
Viral infections (non-CMV)
CD34 selection 6.8 3.1-14.9 <.0001 9.3‡ 3.8-24.4 <.0001
Age, >40 versus ≤40 y 1.1 0.6-2.2 .8
Sex, M versus F 1.1 0.6-1.9 .8
TBI 1.3 0.6-2.6 .5
CMV-positive serostatus prior to transplantation 0.5 0.3-0.8 .01
Use of steroids 2.0 1.1-3.7 .02
Hematological malignancy 1.2 0.7-2.2 .5
Lymphocyte count < 300/mm3 at day 30 1.3 0.3-4.6 .7
Monocyte count < 300/mm3 at day 30 0.9 0.3-2.1 .8
Invasive fungal infections
CD34 selection 3.1 0.8-9.6 .09
Age, >40 versus ≤40 y 1.1 0.4-3.9 .9
Sex, M versus F 0.5 0.1-1.3 .2
TBI 3.9 1.3-11.0 .01
CMV-positive serostatus prior to transplantation 1.0 0.4-3.1 .9
Use of steroids 1.2 0.4-3.2 .8
Hematological malignancy 1.4 0.5-4.1 .5
Lymphocyte count < 300/mm3 at day 30§ — — —
Monocyte count < 300/mm3 at day 30 4.7 1.3-15.2 .02
Invasive bacterial infections
CD34 selection 2.7 1.2-6.0 .02 2.4‡ 1.0-5.7 .06
Age, >40 versus ≤40 y 0.9 0.5-1.9 .8
Sex, M versus F 1.7 1.0-3.1 .07
TBI 1.7 0.8-3.4 .1
CMV-positive serostatus prior to transplantation 0.5 0.3-0.96 .04
Use of steroids 1.2 0.7-2.2 .5
Hematological malignancy 1.7 0.9-3.0 .09
Lymphocyte count < 300/mm3 at day 30 1.8 0.4-6.4 .4
Monocyte count < 300/mm3 at day 30 1.2 0.4-3.1 .7
Any invasive infections
CD34 selection 8.5 3.7-21.9 <.0001
Age, >40 versus ≤40 y 1.1 0.6-1.8 .8
Sex, M versus F 1.3 0.8-2.0 .3
TBI 1.9 1.1-3.4 .03
CMV-positive serostatus prior to transplantation 0.4 0.3-0.7 .0004
Use of steroids 1.4 0.9-2.3 .2
Hematological malignancy 1.4 0.9-2.3 .1
Lymphocyte count < 300/mm3 at day 30 1.4 0.4-4.5 .6
Monocyte count < 300/mm3 at day 30 1.4 0.6-2.9 .4
*CI indicates conﬁdence interval.
†Multivariable models including CD34 selection were ﬁt by adding each of the listed variables in stepwise fashion. Only if the coefﬁcient esti-
mate of CD34 selection changed by more than 10% upon addition of the variable was it kept in the model, and these results are presented.
‡Adding use of TBI to the model changed the coefﬁcient estimate for CD34 selection by >10%.
§Numbers too small to calculate.
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lected PBSC transplant recipients. CD4 count remained
lower in recipients of CD34-selected PBSC. Lymphocyte
recovery was also slower at 1 and 2 months. Unfortunately,
our study was a retrospective analysis, and no data are avail-
able on the immune reconstitution of these patients.
Bacterial infections were also more common in recipi-
ents of CD34-selected transplants. The effect was most pro-
nounced for bacterial site infections and bacteremias (Table 2,
Figure 2). We used strict deﬁnitions for infections and did
not consider bacteremias due to coagulase-negative staphy-
lococci or other bacteria that are generally considered cont-
aminants, such as diphtheroids and non-JK corynebacteria
[23]. The mechanism of this increase in bacterial infections
is unclear. Important risk factors for bacterial infections in
transplant recipients are neutrophil engraftment and use of
corticosteroids. Neither factor differed between the groups
in this study. It is possible that other factors such as the B-cell
content of the PBSC product, monocytes, and cytokine pro-
duction by T-cells may be important, but more studies are
needed to examine this issue.
Invasive fungal infections were somewhat more com-
mon in CD34-selected transplant recipients, but the differ-
ence did not reach statistical signiﬁcance in either univariate
or multivariable models. This result is consistent with a sim-
ilar time to neutrophil engraftment, which has been consid-
ered the most important host defense mechanism for fungal
infections.
Major strengths of this study are the frequency and
consistency of infection surveillance in both groups, the
comprehensive work-up of specimens obtained by invasive
procedures, and the strict deﬁnitions used for invasive infec-
tions. For example, work-up of BAL, biopsy, and autopsy
samples included a wide range of organisms and was done
routinely in all patients. Also, a targeted surveillance system
for respiratory viruses enabled us to obtain specimens from
all patients with upper respiratory symptoms. However, the
retrospective nature of the study is a limitation. Our patients
are generally heavily pretreated as seen in Table 1 and thus
may already be more immunosuppressed prior to CD34
selection. CD34 selection may only heighten the patients’
level of immune dysfunction by further depleting their
number of immune cells and thus make them more suscepti-
ble to infection. In addition, a high proportion of patients
also received TBI and corticosteroid therapy after transplan-
tation, contributing further to their immunosuppression.
Thus, overall infection incidence ﬁgures for CD34-selected
PBSC recipients may be high when compared to those of
other centers where less immunosuppressed patients are
treated [24-26]. Of note, the incidence of infections in
recipients of unmodified PBSC transplant is in agreement
with the incidence in previous studies from our center in
autologous marrow transplant recipients as well as that
observed at other centers [26,27].
In conclusion, recipients of CD34-selected autologous
PBSC transplants are at significantly higher risk for viral
and bacterial infections, and these infections appear to be
severe. The results have direct clinical implications. The
incidence rates of infection for both CMV [10,19] and the
organisms reported in this study suggest that the infection
risk of CD34-selected transplant recipients is similar to that
of allogeneic transplant recipients. Although formal infec-
tion outcome and mortality comparisons with allograft
recipients have not been performed, the morbidity associ-
ated with these infections is significant. Thus, we believe
that infection surveillance, diagnostic approach, and aggres-
sive prophylactic strategies similar to those currently used
for allograft recipients should be employed in CD34-
selected autologous transplant recipients.
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